---
title: "CervoMed 盘中急涨 现涨近 72%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290213110.md"
description: "CervoMed(CRVO.US) 涨 71.92% 报 6.55 美元。获美专利，neflamapimod 治路易体痴呆症至 2042 年。"
datetime: "2026-06-18T14:16:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290213110.md)
  - [en](https://longbridge.com/en/news/290213110.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290213110.md)
---

# CervoMed 盘中急涨 现涨近 72%

CervoMed(CRVO.US) 盘中涨近**72%**，现报**6.55**美元。

消息面上，公司近日获得美国专利商标局批准，neflamapimod 用于纯路易体痴呆症患者的专利保护延长至 2042 年。该药物已完成 2b 期临床试验，3 期试验时间取决于合作伙伴关系或额外融资。

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)

## Related News & Research

- [Cervo posts investor presentation on website covering clinical, development and financial updates](https://longbridge.com/en/news/289829022.md)
- [CervoMed Posts Updated Investor Presentation and Business Overview](https://longbridge.com/en/news/289834335.md)
- [CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | CRVO Stock News](https://longbridge.com/en/news/290228255.md)
- [CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | CRVO Stock News](https://longbridge.com/en/news/289591456.md)
- [Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)](https://longbridge.com/en/news/289519604.md)